Precision BioSciences Provides No Major Clinical Updates; Precision Q2 2021 Earnings Call Summary
Here is a brief preview of this blast: On Thursday, August 12, Precision BioSciences reported their Q2 2021 results (press release) highlighting data presented at ASCO 2021 from PBCAR0191’s Ph1/2a trial in r/r NHL and ALL. Furthermore, management confirmed the dosing of the first patient in both PBCAR19B (stealth CD19 CAR-T) and PBCAR269A (BCMA CAR-T) programs. Below, Celltelligence provides details on Precision’s upcoming milestones.